Targeting Androgen Receptor Activation Function-1 with EPI to Overcome Resistance Mechanisms in Castration-Resistant Prostate Cancer
Abstract
Purpose: Persistent androgen receptor (AR) transcriptional activity is clinically evident in castration-resistant prostate cancer (CRPC). Therefore, AR remains as a viable therapeutic target for CRPC. All current hormonal therapies target the C-terminus ligand-binding domain (LBD) of AR. By using EPI to target AR activation function-1 (AF-1), in the N-terminal domain that is essential for AR transactivation, we evaluate the ability of EPI to overcome several clinically relevant AR-related mechanisms of resistance.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Aug 31, 2016
- Source ID
- 10.1158/1078-0432.ccr-15-2901
Entities
People
- Carmen Adriana Banuelos
- Iain J. Mcewan
- Jun Wang
- Marianne D. Sadar
- Minoru Kato
- Nasrin R. Mawji
- Simon Haile
- Stephen R Plymate
- Yu Chi Yang
Organizations
- BC Cancer Agency
- Canadian Institutes of Health Research
- National Cancer Institute
- United States Army Medical Research and Development Command
- University of Aberdeen
- University of Washington